PAK1 and meningioma: Roberta L. Beauchamp et al. [41] reported that independent activation of SGK1 and PAK1 may be partly responsible for the mTORC1 activation in NF2-deficient meningioma cells, and the group I PAK inhibitor FRAX597 may be improper for treatment for higher concentrations needed.